Key result
Aliskiren reduces hepatic fat ~38% and diminishes liver injury in mice with metabolic syndrome.
Why the study?
Does aliskiren improve hepatic injury and metabolic parameters in a mouse model of metabolic syndrome-related NASH?
Does aliskiren improve hepatic injury and metabolic parameters in a mouse model of metabolic syndrome-related NASH?
Absolute Event Rate: 0.1% vs 0.16%
p-value: p=<0.05
Aliskiren demonstrated beneficial effects on metabolic syndrome-related NASH in a mouse model by reducing hepatic injury, steatosis, and fibrosis.
Aliskiren attenuates NASH features in metabolic syndrome mice; hypothesis-generating, clinical translation untested.
BACKGROUND: Non-alcoholic steatohepatitis (NASH) is highly associated with metabolic syndrome, a major cause of morbidity in the globalized society. The renin-angiotensin system (RAS) influences hepatic fatty acid metabolism, inflammation and fibrosis. Thus, in the present study, we aimed to evaluate the effect of aliskiren, a direct renin inhibitor, on metabolic syndrome-related NASH. METHODS: C57BL/6 male mice (n = 45) were divided into three groups: controls; animals inoculated with streptozotocin (STZ) (40 mg/kg/day) for 5 days and fed with high fat diet (HFD) for 8 weeks; and animals inoculated with STZ for 5 days, fed with HFD for 8 weeks and treated with aliskiren (100 mg/kg/day) for the final 2 weeks. Glycemic and insulin levels, hepatic lipid profile, histological parameters and inflammatory protein expression were analyzed. RESULTS: Aliskiren normalized plasma glucose and insulin levels, reduced cholesterol, triglycerides and total fat accumulation in liver and diminished hepatic injury, steatosis and fibrosis. These results could be explained by the ability of aliskiren to block angiotensin-II, lowering oxidative stress and inflammation in liver. Also, it exhibited a beneficial effect in increasing insulin sensitivity. CONCLUSION: These findings support the use of aliskiren in the treatment of metabolic syndrome underlying conditions. However, clinical studies are indispensable to test its effectiveness in the treatment of patients with metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Ramalho et al. (2017) studied Non-alcoholic steatohepatitis (NASH) in metabolic syndrome (n=45). Aliskiren vs. Diabetes and high fat diet (HDC) without aliskiren was evaluated on Hepatic total fat (mg/g) (p=<0.05). Aliskiren significantly reduced hepatic total fat (0.10 vs 0.16 mg/g) and diminished hepatic injury, steatosis, and fibrosis in mice with metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: